Article content The claims in question included that, “cannabidiol can change gene expression and remove beta-amyloid plaque, the hallmark of Alzheimer’s, from brain cells” and that “scientific and clinical studies have shown that CBD could be therapeutic for many conditions.” That long list of these conditions includes chronic pain, cancer, diabetes, sleep disorders, rheumatoid arthritis, post-traumatic stress disorder, alcoholism and neurological ailments, notes the SCDAO release. As a member of the California Food, Drug and Medical Device Task Force, the SCDAO and CannaCraft reached a settlement in the consumer protection false advertising action. In opting to settle, Judge Thomas W. Wills reported Sonoma County-based CannaCraft will pay US$250,000 ($302,500) in civil penalties, US$25,000 ($30,250) in